



04-02-02
57

#5 1623

Patent Application
Attorney Docket No. PC10743A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Alan, et al. :

APPLICATION NO.: 09/884,211

: Examiner: Not Yet Assigned

FILING DATE: June 18, 2001

: Group Art Unit: 1623

TITLE: NOVEL MELANOCORTIN-4
RECEPTOR SEQUENCES AND
SCREENING ASSAYS TO IDENTIFY
COMPOUNDS USEFUL IN
REGULATING ANIMAL APPETITE
AND METABOLIC RATE

TECH CENTER 1600/2900

APR 05 2002

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicants belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.



Patent Application
Attorney Docket No. PC10743A

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: April 1, 2002

Lorraine B. Ling
Lorraine B. Ling
Attorney for Applicant(s)
Reg. No. 35,251

Pfizer Inc
Patent Department
150 East 42nd Street - 105/5/49
New York, NY 10017-5612
(212) 573-2030